These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 29502984)

  • 21. Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women.
    Clayton AH; Dennerstein L; Pyke R; Sand M
    Womens Health (Lond); 2010 Sep; 6(5):639-53. PubMed ID: 20887163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flibanserin Efficacy and Safety in Premenopausal Women With Generalized Acquired Hypoactive Sexual Desire Disorder.
    Fisher WA; Pyke RE
    Sex Med Rev; 2017 Oct; 5(4):445-460. PubMed ID: 28666836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ignorance Is Not Bliss: If We Don't Understand Hypoactive Sexual Desire Disorder, How Can Flibanserin Treat It? Commentary.
    Anderson R; Moffatt CE
    J Sex Med; 2018 Mar; 15(3):273-283. PubMed ID: 29396022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flibanserin.
    Vallejos X; Wu C
    J Pharm Pract; 2017 Apr; 30(2):256-260. PubMed ID: 26873507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Timing of Flibanserin Administration Relative to Alcohol Intake in Healthy Premenopausal Women: A Randomized, Double-Blind, Crossover Study.
    Simon JA; Clayton AH; Kingsberg SA; Parish SJ; Kim NN; Millheiser L
    J Sex Med; 2019 Nov; 16(11):1779-1786. PubMed ID: 31522985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flibanserin for female sexual dysfunction.
    Reviriego C
    Drugs Today (Barc); 2014 Aug; 50(8):549-56. PubMed ID: 25187905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weight Loss in Women Taking Flibanserin for Hypoactive Sexual Desire Disorder (HSDD): Insights Into Potential Mechanisms.
    Simon JA; Kingsberg SA; Goldstein I; Kim NN; Hakim B; Millheiser L
    Sex Med Rev; 2019 Oct; 7(4):575-586. PubMed ID: 31196764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
    Althof S; Derogatis LR; Greenberg S; Clayton AH; Jordan R; Lucas J; Spana C
    J Sex Med; 2019 Aug; 16(8):1226-1235. PubMed ID: 31277966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy and safety of flibanserin "new female Viagra
    Terrier C; Terrier JE
    Prog Urol; 2016; 26(11-12):592-599. PubMed ID: 27663307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of safety for flibanserin.
    Clayton AH; Brown L; Kim NN
    Expert Opin Drug Saf; 2020 Jan; 19(1):1-8. PubMed ID: 31855607
    [No Abstract]   [Full Text] [Related]  

  • 31. Flibanserin and Female Sexual Desire.
    Fantasia HC
    Nurs Womens Health; 2016; 20(3):309-14. PubMed ID: 27287358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacodynamic effects of combined administration of flibanserin and alcohol.
    Stevens DM; Weems JM; Brown L; Barbour KA; Stahl SM
    J Clin Pharm Ther; 2017 Oct; 42(5):598-606. PubMed ID: 28608926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic Review and Meta-analysis of Flibanserin's Effects and Adverse Events in Women with Hypoactive Sexual Desire Disorder.
    Saadat SH; Kabir A; Rahmani K; Panahi Y; Hosseinialhashemi M; Sahebkar A
    Curr Drug Metab; 2017; 18(1):78-85. PubMed ID: 27784209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flibanserin and its discontents.
    Aftab A; Chen C; McBride J
    Arch Womens Ment Health; 2017 Apr; 20(2):243-247. PubMed ID: 27858170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flibanserin: From Bench to Bedside.
    Dooley EM; Miller MK; Clayton AH
    Sex Med Rev; 2017 Oct; 5(4):461-469. PubMed ID: 28757356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Tribulus Terrestris for the treatment of premenopausal women with hypoactive sexual desire disorder: a randomized double-blinded, placebo-controlled trial.
    Vale FBC; Zanolla Dias de Souza K; Rezende CR; Geber S
    Gynecol Endocrinol; 2018 May; 34(5):442-445. PubMed ID: 29172782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the Sexual Desire Relationship Distress Scale (SDRDS) in women with hypoactive sexual desire disorder.
    Revicki DA; Margolis MK; Fisher W; Rosen RC; Kuppermann M; Hanes V; Sand M
    J Sex Med; 2012 May; 9(5):1344-54. PubMed ID: 22376073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
    Parish SJ; Simon JA; Davis SR; Giraldi A; Goldstein I; Goldstein SW; Kim NN; Kingsberg SA; Morgentaler A; Nappi RE; Park K; Stuenkel CA; Traish AM; Vignozzi L
    J Sex Med; 2021 May; 18(5):849-867. PubMed ID: 33814355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and Predictors of Low Sexual Desire, Sexually Related Personal Distress, and Hypoactive Sexual Desire Dysfunction in a Community-Based Sample of Midlife Women.
    Worsley R; Bell RJ; Gartoulla P; Davis SR
    J Sex Med; 2017 May; 14(5):675-686. PubMed ID: 28499520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of premenopausal and postmenopausal women with acquired, generalized hypoactive sexual desire disorder: the Hypoactive Sexual Desire Disorder Registry for women.
    Rosen RC; Maserejian NN; Connor MK; Krychman ML; Brown CS; Goldstein I
    Menopause; 2012 Apr; 19(4):396-405. PubMed ID: 22076307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.